
Pharmacy Practice in Focus: Health Systems
- November 2026
- Volume 15
- Issue 6
Updates on Glucagon-Like Peptide-1 Receptor Agonists for Diabetes and Obesity
Higher doses of injectable semaglutide have been shown to cause greater weight loss than standard doses with a similar safety profile.
The use of glucagon-like peptide-1 (GLP-1) receptor agonists has rapidly grown in the United States, with reported use increasing by 230% in patients with diabetes and by more than 600% in patients without diabetes over the 5-year period from 2017 to 2022.1 Recent GLP-1 receptor agonists approved by the FDA in 2026 include high-dose semaglutide (Wegovy HD; Novo Nordisk) and the small-molecule, nonpeptide oral GLP-1 receptor agonist orforglipron (Foundayo; Lilly). These agents add to a number of GLP-1 receptor agonists indicated for diabetes and/or weight loss in adults. Both orforglipron and high-dose semaglutide carry indications for short-term reduction and for the long-term maintenance of weight reduction in adult patients with obesity or overweight.2,3 Clinical studies found that higher doses of semaglutide resulted in additional mean weight reductions compared with previously approved doses, with a similar safety profile. In patients with obesity and type 2 diabetes, there was a similar lowering of hemoglobin A1c (HbA1c) with higher doses of semaglutide compared with lower doses.2 This review highlights pivotal phase 3 clinical trials for these agents and discusses emerging safety evidence within this class.
Related to this article








